Abstract 114P
Background
Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.
Methods
A cross-sectional cohort study was conducted to assess PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.
Results
We incluided 201 patients, of which 43 (21.4%) exhibited PGVs, identifying that 64.5% occurred in DNA damage repair genes, being 86.1% clinically actionable. The most frequent PGVs were found in ATM (9.3%), TP53 (6.9%), BRCA2 (6.9%), and CHEK2 (6.9%) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.54, 95% CI 1.17–5.53, p=0.019), very young-onset presentation (aOR 5.79, 95% CI 1.35–24.74, p=0.018), and first-degree relatives with LC (aOR 3.78, 95% CI 1.11–12.83, p=0.033), along with a trend toward association with AGAs (aOR 6.42, 95% CI 0.79–52.18, p=0.082).
Conclusions
This study identified a high PGVs prevalence based on our selection criteria, thus representing an effective strategy to select candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.
Clinical trial identification
NCT06181812.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by CONAHCyT (A3-S-47960) and Becas Impulso a La Investigación En Salud “Carlos Slim” 2023 (N20230149).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)
Presenter: Anthony Tolcher
Session: Poster session 08
194P - CD8-to-CD20 lymphocyte ratio is a predictive biomarker for lenvatinib and pembrolizumab efficacy and progression-free survival in advanced endometrial cancer: Updated data
Presenter: Liubov Tashireva
Session: Poster session 08
195P - Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
Presenter: Eva Colas
Session: Poster session 08
196P - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Presenter: Richard Schlenk
Session: Poster session 08
197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials
Presenter: Tina Kringelbach
Session: Poster session 08
198P - Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 08
199P - Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival
Presenter: qingsheng xie
Session: Poster session 08
200P - Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Presenter: Tilmann Bochtler
Session: Poster session 08
201P - Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2
Presenter: Takao Fujisawa
Session: Poster session 08